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Abstract
Methionine (Met) loading increases total plasma homocysteine (tHcy) and assesses homocysteine
metabolism. We tested the hypothesis that pre- or post-Met tHcy will predict recurrent stroke or
coronary artery disease (CAD) in a subgroup analysis of the Vitamin Intervention for Stroke
Prevention (VISP) trial. VISP subjects with non-disabling stroke underwent measurement of tHcy
at baseline (fasting pre- and post-Met load) and were randomized to high/low-dose B-vitamin
therapy for prevention of recurrent stroke or CAD. In the sample cohort of 2,124 subjects, mean ±
SD tHcy levels in µmol/L were: pre-Met 13.2 ± 4.3, post-Met 30.4 ± 9.76, and pre/post-Met Δ
17.1 ± 8.3. The hazard ratio (HR) for recurrent stroke was 1.16 (p=0.026) for 1 SD higher pre-Met
tHcy and 1.15 (p=0.054) for 1 SD higher post-Met tHcy. For CAD, the HR for 1 SD higher pre-
Met tHcy was 1.27 (p=0.001) and was 1.00 (p=0.99) for post-Met tHcy. In survival analyses using
pre- or post-Met as covariates, the coefficient of pre/post-Met Δ was not significant for stroke and
was only marginally significant for CAD (p<0.08), but was negative. We conclude that fasting,
pre-Met tHcy is as effective as post-Met tHcy or pre/post-Met Δ in predicting the risk for stroke
and CAD.
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Homocysteine is a sulfhydryl amino acid product of methionine metabolism. Case-control
studies performed in subjects with moderate hyperhomocysteinemia show that elevated
homocysteine, obtained after fasting or methionine loading, is an independent risk factor for
premature coronary artery disease (CAD), stroke, or peripheral vascular disease resulting
from atherosclerosis.1, 2 Mechanisms by which homocysteine may cause occlusive vascular
disease in the heart and brain include increased propensity for thrombosis, impaired
thrombolysis, increased production of hydrogen peroxide, endothelial dysfunction, and
increased oxidation of low-density lipoprotein.3–5
To identify hyperhomocysteinemia more sensitively, oral loading with methionine has been
used to determine the content of acid-soluble homocysteine that is present only in low
concentrations in fasting plasma. In a cohort drawn from the NHLBI Family Heart Study,
57% of hyperhomocysteinemic individuals were identified from tHcy levels obtained after
fasting and before methionine loading.6 The remaining 43% required assay of tHcy after
methionine loading or calculation of the difference between pre- and post-load levels. In a
case-control study of tHcy as a predictor of vascular disease risk examined within the
European Concerted Action Project, Graham and colleagues found that reliance only on
fasting tHcy classified 27% fewer patients as hyperhomocysteinemic.7
Recognizing that methionine loading is reported to more accurately define
hyperhomocysteinemia, we evaluated the comparative utility of tHcy sampled after fasting
or methionine loading and by calculation of the pre-post load difference in tHcy for
prediction of symptomatic atherothrombotic disease. We examined tHcy levels obtained
before or after methionine loading in patients with non-disabling cerebral infarction (NDCI)
who were enrolled in the Vitamin Intervention for Stroke Prevention (VISP) clinical trial. In
this subgroup analysis of VISP, we tested the hypothesis that tHcy assayed only after fasting
will be equivalent to the level obtained after methionine loading or by pre-post load
difference in tHcy for prediction of recurrent stroke or symptomatic CAD.
Subjects and Methods
The rationale, design, and results of the VISP trial have been published.8, 9 Briefly, VISP
was a randomized, prospective, double-masked, multi-center clinical trial of secondary
stroke prevention that compared high- to low-dose B-vitamin therapy. The primary outcome
measure was recurrent stroke. Secondary outcome measures included symptomatic CAD
and all-cause death. Screening samples for quantification of plasma tHcy were obtained
from patients recruited within 120 days of a qualifying NDCI. If shown to be eligible by a
screening tHcy level that exceeded 25th percentile for a benchmark population, the subject
would be scheduled for a randomization visit during which tHcy levels were obtained before
and after a methionine loading test.
Methionine loading was performed as described in our original report.8 Each subject was
fasted overnight and a sample of whole blood for tHcy assay was obtained before the
methionine load (pre-Met). The subject was then given methionine (0.1 g/kg body weight)
as a crystalline powder dissolved in 227 ml (8 ounces) of unsweetened fruit juice. Two
hours after the methionine load, a second whole blood sample was obtained for post-
methionine load (post-Met) tHcy. The absolute difference between pre- and post-methionine
load tHcy was also calculated (pre/post-Met Δ).
Each whole blood specimen for tHcy analysis was drawn in duplicate, using vacutainer
tubes containing EDTA that were light-sealed and centrifuged to prepare plasma aliquots for
assay by high-performance liquid chromatography (HPLC).10–12 For quality control,
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replicate plasma aliquots were obtained from a sample of study participants (n=283) and
sent to the central laboratory with different identifiers. The inter-run coefficient of variation
for tHcy was 0.08 and the correlation between repeat measurements of blind replicates was
0.94.8
To identify variables associated with pre/post-Met Δ, we used Pearson correlation
coefficients for univariate association and multiple linear regression models for joint
association. The associations between two different tHcy variables and survival outcomes
such as recurrent stroke and CAD were modeled by the Cox proportional hazard regression
model after adjusting for key covariates at baseline (i.e., vitamin dose, age, sex, and race). In
this model, pre/post-Met Δ was added to see if the new marker increased predictability of
outcome. We also implemented the Receiver Operating Characteristic (ROC) curve and
calculated the area under the curve (AUC) in order to assess the diagnostic properties of key
tHcy variables. The AUCs of the indices were compared using a non-parametric method.13
We used SAS software, version 8 (SAS Institute Inc., Cary, NC) for all statistical analyses.
Two-sided hypotheses were adopted for statistical inference.
Results
After excluding subjects with insufficient fasting time (< 8 hours) or missing pre- or post-
Met tHcy levels (n=1,550) and others with extreme tHcy levels, pre-Met tHcy > 50 µmol/L
or post-Met tHcy > 80 µmol/L, that were suspected to be outliers (n=6), 2,124 patients
remained in the sample cohort drawn from the entire VISP population. Within this cohort,
166 subjects had recurrent stroke (7.8%) during their participation in VISP and 123 had
symptomatic CAD (5.8%). In the intention-to-treat population randomized for the VISP trial
(n = 3,680), 300 subjects had a recurrent stroke (8.2%) and 237 had symptomatic CAD
(6.4%). Table 1 presents summary statistics for key baseline characteristics of the sample
cohort in comparison to the VISP population.
In this sample cohort drawn from the VISP population, mean ± standard deviation (SD)
tHcy levels in µmol/L were: pre-Met 13.2 ± 4.3, post-Met 30.4 ± 9.76, and pre/post-Met Δ
17.1 ± 8.3. We found that pre/post-Met Δ correlated strongly with post-Met tHcy, but
weakly with pre- Met tHcy. The Pearson correlation coefficient between pre/post-Met Δ and
post-Met tHcy was 0.87 but was only 0.11 with pre-Met tHcy (p < 0.0001). The correlation
coefficient between pre-and post-Met tHcy was stronger at 0.56 (p < 0.0001).
To evaluate the association between pre/post-Met Δ and pre-specified prognostic factors, we
considered pre-Met tHcy, some important demographic variables (age, sex and race), and
randomly assigned treatment, as listed in Table 2. A standard multiple linear regression
model was adopted for this analysis. It was shown that pre-Met tHcy and pre/post-Met Δ
were positively associated in the multiple linear regression model. We found that pre/post-
Met Δ increases were smaller in older subjects (0.12 µmol/L lower per year of age) but were
larger in women than in men (by 5.1 µmol/L) and in whites than in blacks (by 4.6 µmol/L),
all of which were highly significant (p < 0.0001).
Next, the assumption of proportionality of hazards was tested and the use of the Cox model
was justified.14 Hazard ratios (HRs) for recurrent stroke or symptomatic CAD, as calculated
in survival analysis models using pre- or post-Met tHcy as the predictive variable, are shown
in Table 3. The HR for recurrent stroke was 1.16 (p=0.026) for 1 SD higher pre-Met tHcy
and 1.15 (p=0.054) for 1 SD higher post-Met tHcy. For CAD, the HR associated with 1 SD
higher pre-Met tHcy was 1.27 (p=0.001) and was 0.998 (p=0.985) for 1 SD higher post-Met
tHcy. The effect of pre/post-Met Δ, without accounting for individual tHcy, was not
statistically significant for either endpoint. The HR of pre/post-Met Δ was significantly
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different from the null when added to the survival model using pre-Met tHcy to predict CAD
(p=0.027), but showed some protective effects. When added to the model using pre-Met
tHcy to predict recurrent stroke, it was not significant. Since post-Met and pre/post-Met Δ
are highly correlated, they were not included jointly in any regression analysis. The HRs
shown in Table 3 correspond to a 1-standard deviation increase of the respective factor (pre-
or post-Met load or pre/post-Met Δ considered singly), assuming other conditions remain
fixed. In all other cases, the HRs were examined under conditions that permitted two
dependent factors (e.g., pre-Met and pre/post-Met Δ) to be varied jointly.
Table 4 summarizes the results from the ROC/AUC analysis. It is notable that pre-Met tHcy
improves the risk predictability of each cardiovascular outcome beyond the key baseline
factors (p = 0.05), unlike post-Met tHcy. However, an increased predictive ability by the
additional use of pre/post-Met Δ information is only borne out in prediction of symptomatic
CAD (p=0.03).
We attempted to correct the HRs for potential measurement errors in tHcy using reliability
coefficients obtained from Tsai and co-workers.15 Although VISP was not designed to
assess the statistical implications of tHcy measurement errors, some sense of the potential
impact of this error may be obtained through externally applied reliability coefficients. After
this correction, pre-Met tHcy showed an increase in HR of 7 – 10% while the increase in HR
observed with post-Met tHcy did not exceed 3%, as applied to prediction of either recurrent
stroke or symptomatic CAD.
Discussion
The most important finding in this subgroup analysis of the VISP trial is that pre-Met tHcy
was comparable to post-Met or pre/post-Met Δ in predicting risk of both recurrent stroke
and symptomatic CAD. In predicting recurrent stroke, we found that elevation of fasting,
pre-Met tHcy above 1 SD was the most effective prognosticator among the variables that we
examined, that the same threshold in post-Met tHcy was less sensitive (as shown by less
stringent p value in HR calculation on survival analysis), and that pre/post-Met Δ was
ineffective. For predicting symptomatic CAD, elevation of pre-Met tHcy was strongly
associated with increased risk, although the same threshold in post-Met tHcy was
insignificant. Addition of pre/post-Met Δ in multivariate regression models predicting
symptomatic CAD was statistically significant, although with protective effects. The role of
pre/post-Met Δ was meaningful only when considered together with pre-Met value; the
associations with the outcome became stronger and prediction was improved. Our analysis
suggests that pre-Met tHcy is the most powerful and effective predictor of CAD risk, as it is
for recurrent stroke, that post-Met tHcy is not predictive, and that pre/post-Met Δ may be
more useful in prediction of CAD than of stroke. These conclusions are strengthened by
deriving qualitatively similar risk profiles for both stroke and CAD from two different
statistical techniques (i.e., survival and ROC analyses).
We recognize that observations drawn from this subgroup analysis may be limited by its
evaluation of a cohort group defined within the original VISP population.16, 17
Furthermore, it is possible that the statistical power of this study could be influenced by lack
of subject compliance with study treatment in VISP or incomplete acquisition of data in an
extended, longitudinal trial.18 However, our use of this approach is strengthened by
adherence to guidelines recommended for valid subgroup analyses of clinical trials.19 It is
important to note that we did not conduct standard multivariate regression modeling (with
comprehensive adjustment for covariates) to identify novel risk factors or to duplicate
validation of tHcy as an independent risk factor for cardiovascular disease.1, 2 Our goal in
this subgroup analysis was to compare and evaluate the relative importance of pre and post-
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Met tHcy for prediction of two major outcomes of the VISP trial, recurrent stroke and CAD.
In following this approach, we chose minimally-adjusted statistical models (focused on
cohort demographics and treatment assignment only) and employed standard techniques
such as proportional hazards modeling and ROC analysis to strengthen and simplify our
conclusions.
As shown in Table 1, there was relatively symmetric clustering of both pre- and post-Met
tHcy between the sample cohort and the base population in VISP, although the two differed
by several characteristics and did not have uniform fasting times (12 hours for the sample
cohort and 8 hours for the base population in VISP). The baseline cobalamin level was
lower in the sample cohort than in the VISP population, but both remained well above
thresholds defining cobalamin deficiency in routine clinical practice and in the VISP trial.8
Overall, the magnitude of these statistically significant differences remained limited, thereby
suggesting that the cohort was representative of all subjects enrolled in VISP.
Variability in tHcy levels may be caused by unfavorable lifestyle factors, renal
insufficiency, concomitant use of phenytoin, and dietary supplementation with B-vitamins,
20 all of which were controlled or excluded in the VISP clinical trial. Post-Met tHcy may be
heavily influenced by polymorphisms in the human gene for methylenetetrahydrofolate
reductase (MTHFR), the folate-dependent enzyme that converts approximately 50% of
circulating homocysteine into methionine. In a large study of tHcy levels assayed before and
after methionine loading in 51 Dutch pedigrees, the 677C>T MTHFR genotype accounted
for 67.5% of post-Met tHcy heritability (genetically explained variance/total variance) but
had no effect on fasting tHcy.21 Although MTHFR genotyping was not performed in VISP,
we excluded patients with pre-Met tHcy > 50 µmol/L or Post-Met tHcy > 80 µmol/L as
outliers who could harbor undiscovered MTHFR polymorphisms.
This study describes the largest reported cohort of individuals in which fasting, pre-Met
tHcy has been compared to post-Met tHcy and pre/post-Met Δ for stratification of
atherothrombotic risk. We conclude that fasting tHcy without Met loading is comparable to
post-Met tHcy or pre/post-Met Δ for prediction of recurrent stroke and CAD in high-risk
patients with hyperhomocysteinemia. We propose that fasting tHcy be quantified routinely
for stratification of vascular risk in patients with mild stroke or transient ischemic attack.
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Table 1
Comparison of Baseline Characteristics and Endpoints between the VISP Population and a Sample Cohort
Selected for Prediction of Stroke and Coronary Artery Disease (CAD) Risk from Homocysteine Levels with
or without Methionine Loading
All VISP Participants (N=3,680) Sample Cohort for Prediction of Stroke and Coronary Artery
Disease Risk (N=2,124)
p-value*
Age (years) 66.3 ± 10.8 66.1 ± 10.9 0.097
Sex
   Male 2,301 (62.5%) 1,373 (64.6%) 0.002
   Female 1,379 (37.5%) 751 (35.4%)
Race
   White 2,925 (79.5%) 1,713 (80.7%) 0.067
   Black 545 (14.8%) 290 (13.7%)
   Other races 210 (5.7%) 121 (5.7%)
Cholesterol level (mg/dl)
   Total 201.9 ± 46.7 203.1 ± 46.0 0.07
   LDL 122.3 ± 40.1 123.9 ± 39.7 0.007
   HDL 45.4 ± 15.5 45.9 ± 15.8 0.026
Blood pressure (mm Hg)
   SBP 140.8 ± 18.7 140.6 ± 18.5 0.38
   DBP 77.9 ± 10.1 78.1 ± 9.8 0.21
B12 (ng/ml) 361.5 ± 228.5 351.5 ± 205 0.002
Pre-Met tHcy (µmol/L) 13.4 ± 5.1 13.2 ± 4.3 0.012
Post-Met tHcy (µmol/L) 29.8 ± 10.4 30.4 ± 9.8 <0.001
Pre/post-Met Δ 16.5 ± 8.9 17.2 ± 8.3 <0.001
Smoking 621 (16.9%) 391 (18.4%) 0.004
Recurrent Stroke 300 (8.2%) 166 (7.8%) **
Coronary Artery Disease 237 (6.4%) 123 (5.8%) **
All continuous variables are summarized as means ± standard deviations and categorical variables are expressed as numbers of subjects and
corresponding percentages of the base population.
*
p-value for testing the difference of each factor between the subjects included vs. the subjects excluded in the analysis. The t-test for continuous
variables and the chi-square test for categorical variables were adopted for p value calculation.
**
This Table shows no statistical comparison of the study endpoints (recurrent stroke and coronary artery disease) because these were censored
survival outcomes and are described in Table 3.
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Table 2
Variables Associated with Pre/Post-Methionine Difference (Δ) in Total Plasma Homocysteine (tHcy) Using a
Multiple Linear Regression Model
Estimate (Standard Error) p-value
Pre-Met tHcy (µmol/L) 0.27 (0.03) <.0001
Treatment (H vs. L1) 0.35 (0.34) 0.30
Age (1 year increase) −0.12 (0.02) <.0001
Sex (women vs. men) 5.08 (0.36) <.0001
Race (black vs. white) −4.59 (0.50) <.0001
1
H vs. L: High- vs. low-dose B vitamins in VISP formulation
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Table 3
Hazard Ratios1 for Recurrent Stroke or Symptomatic Coronary Artery Disease as Predicted by Total Plasma
Homocysteine before or after Methionine Loading
Stroke Coronary Artery Disease
Sample of Total Plasma Homocysteine Hazard Ratio (95% C.I.) p-Value Hazard Ratio (95% C.I.) p-Value
Pre-Methionine Load 1.16 (1.02, 1.33) 0.026 1.27 (1.10, 1.46) 0.001
Post-Methionine Load 1.15 (1.00, 1.33) 0.054 1.00 (0.83, 1.20) 0.985
Pre/Post-Met Δ 1.09 (0.94, 1.28) 0.254 0.83 (0.67, 1.02) 0.077
Pre-Methionine Load2 1.15 (1.01, 1.32) 0.041 1.30 (1.12, 1.49) 0.0004
Pre/post-Met Δ2 1.07 (0.91, 1.24) 0.427 0.79 (0.64, 0.97) 0.027
1
Hazard ratios were computed from a Cox proportional hazard regression model, adjusting for treatment group, age, sex, and race and correspond
to 1 standard deviation increase (i.e., 4.3 for Pre-Met; 9.8 for Post-Met; 8.3 for Pre/post-Met Δ).
2
Pre-Met and Pre/post-Met Δ are included together in the same regression model.
C.I. denotes confidence interval.
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Table 4
Diagnostic Characteristics for Predicting Endpoints (Recurrent Stroke and Coronary Artery Disease) in
Sequentially Constructed Models
Stroke Coronary Artery Disease
Model1 AUC2 p-value3 AUC2 p-value3
Model 1 0.557 0.620
Model 2 0.575 0.23 0.648 0.05
Model 3 0.563 0.67 0.621 0.45
Model 4 0.573 0.38 0.658 0.03
Model 5 0.573 0.38 0.658 0.03
1
Model 1 is a baseline model with the covariates of treatment, age, sex and race;
Model 2 is Model 1, additionally adjusting Pre-Met tHcy;
Model 3 is Model 1, additionally adjusting Post-Met tHcy;
Model 4 is Model 1, additionally adjusting Pre-Met tHcy and Pre/post-Met Δ;
Model 5 is Model 1, additionally adjusting Post-Met tHcy and Pre/post-Met Δ.
2
AUC: Area under ROC Curve
3
p-value for testing if there is a significant AUC improvement by using the given model, compared to model 1.
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